<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03420534</url>
  </required_header>
  <id_info>
    <org_study_id>ZDY2017002</org_study_id>
    <nct_id>NCT03420534</nct_id>
  </id_info>
  <brief_title>Human Bioequivalence Test (Fasting &amp; Postprandial) of Iloperidone Tablets</brief_title>
  <official_title>Human Bioequivalence Test (Fasting &amp; Postprandial) of Iloperidone Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to inspect relevant pharmacokinetic parameters and relative exploitation degree, with fasting
      and postprandial dosing bioequivalence test under the condition of the human body, provide
      the basis for registration filing.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Anticipated">March 14, 2018</completion_date>
  <primary_completion_date type="Actual">December 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,</measure>
    <time_frame>Change from Baseline afer dosing 0.33h,0.67h,1h,1.5h,2h,2.5h,3h,4h,6h,8h,12h ,24h,36h,48h,72h,96h,120h.</time_frame>
    <description>Peak Plasma Concentration (Cmax) of iloperidone and metabolite P88</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Change from Baseline afer dosing 0.33h,0.67h,1h,1.5h,2h,2.5h,3h,4h,6h,8h,12h ,24h,36h,48h,72h,96h,120h.</time_frame>
    <description>Tmax time to Peak Plasma Concentration (Cmax) of iloperidone and metabolite P88</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t、AUC0-∞</measure>
    <time_frame>Change from Baseline afer dosing 0.33h,0.67h,1h,1.5h,2h,2.5h,3h,4h,6h,8h,12h ,24h,36h,48h,72h,96h,120h.</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of iloperidone and metabolite P88</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2,</measure>
    <time_frame>Change from Baseline afer dosing 0.33h,0.67h,1h,1.5h,2h,2.5h,3h,4h,6h,8h,12h ,24h,36h,48h,72h,96h,120h.</time_frame>
    <description>t1/2, half-life period of iloperidone and metabolite P88</description>
  </primary_outcome>
  <primary_outcome>
    <measure>F</measure>
    <time_frame>Change from Baseline afer dosing 0.33h,0.67h,1h,1.5h,2h,2.5h,3h,4h,6h,8h,12h ,24h,36h,48h,72h,96h,120h.</time_frame>
    <description>F bioavalibility of iloperidone and metabolite P88</description>
  </primary_outcome>
  <primary_outcome>
    <measure>λz</measure>
    <time_frame>Change from Baseline afer dosing 0.33h,0.67h,1h,1.5h,2h,2.5h,3h,4h,6h,8h,12h ,24h,36h,48h,72h,96h,120h.</time_frame>
    <description>λz eliminating rate of iloperidone and metabolite P88</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>iloperidone in fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iloperidone 1mg by mouth once for 6 days in the first cycle or the second cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo tablets in fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo mimic iloperidone 1mg by mouth once for 6 days in the second cycle or the first cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo tablets in postprandial</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo mimic iloperidone 1mg by mouth once for 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iloperidone in postprandial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iloperidone 1mg by mouth once for 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloperidone 1 MG</intervention_name>
    <description>An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.</description>
    <arm_group_label>iloperidone in fasting</arm_group_label>
    <arm_group_label>placebo tablets in postprandial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.</description>
    <arm_group_label>placebo tablets in fasting</arm_group_label>
    <arm_group_label>iloperidone in postprandial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fasting</intervention_name>
    <description>An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.</description>
    <arm_group_label>iloperidone in fasting</arm_group_label>
    <arm_group_label>placebo tablets in fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>postprandial</intervention_name>
    <description>An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.</description>
    <arm_group_label>placebo tablets in postprandial</arm_group_label>
    <arm_group_label>iloperidone in postprandial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1) age above 18 years of age (including 18 years of age), male or female; 2) body mass
        index (BMI) = weight (kg)/height 2 (m2) , body mass index (including critical value) within
        18~26 range; 3) health: no heart, liver, kidney, gastrointestinal tract, nervous system,
        mental disorder and metabolic abnormalities, such as history, physical examination showed
        the blood pressure, heart rate, ecg, respiratory system, liver, kidney, and normal or
        abnormal urinalysis performed without clinical significance; 4) subjects (including male
        subjects) are willing to take effective contraceptive measures in the next three months
        without pregnancy plan.

        5) sign the informed consent before the test, and fully understand the contents, procedures
        and possible adverse reactions of the test; 6) be able to complete the research according
        to the test plan.

        Exclusion Criteria:

        - 1) HBsAg, HBeAg, HCV antibody, HIV antibody, and treponema pallidum are positive; 2)
        general physical examination, blood biochemistry, blood urine routine, serum prolactin and
        ECG examination are abnormal and have clinical significance; 3) past history or current in
        clinic with heart, breathing, endocrine, metabolism, kidney, liver, gastrointestinal tract,
        skin, infection, malignant tumor, blood and nerve system disease or mental/disorders; 4)
        take any medication, including over-the-counter and herbal medicines, within two weeks
        prior to the start of the trial; 5) the subjects' drinking history was more than 14 units
        of alcohol per week (1 unit = beer 285 mL, or liquor 25 mL, or wine 150 mL) or alcohol
        breath test was positive; 6) currently smoking &gt;5 per day; 7) drug abuse or drug dependence
        or urine drug screening positive; 8) blood donation or a large amount of blood loss (&gt;400
        mL) or as a subject participating in drug trial sampling in the last three months; 9)
        underwent surgery within 4 weeks prior to the trial, or planned to perform surgical
        procedures during the study period; 10) test within 48 h before taking any special diet
        (including grapefruit, etc.), and/or contain xanthine diet or strenuous exercise, or other
        affect drug absorption, distribution, metabolism and excretion of food or drink, etc.; 11)
        drink excessive amounts of tea, coffee and/or caffeinated beverages (8 cups or more, 1 cup
        =250 mL) per day; 12) QTc period is greater than 450ms (male) or 470ms (female), or there
        is a history of QTc extension; 13) postural hypotension (the systolic blood pressure drops
        by 20mmHg or diastolic blood pressure drops by 10mmHg after standing on the supine
        position) 14) during the screening period or during the test, the female subjects were
        positive in lactation or pregnancy.

        15) the researchers judged that the subjects' ability to comply with the research
        requirements was not necessarily complete or not necessarily able to comply with the
        subjects required by the test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The first affiliated hospital of zhengzhou university.</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

